Key precious metals have been on an incredible run in recent months, fueled by investor uncertainty amid a shifting tariff landscape, trade tensions between the United States and China, and other ongoing geopolitical volatility. Gold has led the way, surging by more than 41% in the year leading to late April 2025, although silver and platinum have also solidly outperformed the broader market during the same time period. Investors may be able to capitalize on precious metals' continued success through target ...

For 3 months of 2025, the unaudited consolidated net profit of the INVL Baltic Real Estate (hereinafter – the Company) group was EUR 0.14 million, revenue was EUR 0.93 million (for 3 months of 2024 consolidated net profit was EUR 0.22 million, revenue was EUR 1.05 million). The unaudited net profit of Company itself amounted to EUR 0.14 million for 3 months of 2025 and EUR 0.22 million for 3 months of 2024. The decrease in the profit and revenue was mainly due to the sale of part of the Dommo Biznesa Parks ...

30 April 2025 – Prosafe SE today published the Annual report, Transparency Act Statement and Remuneration report for 2024. The Annual report includes the 2024 annual accounts, corporate governance report and sustainability report. On 31 January 2025, Prosafe reported preliminary and unaudited results for the fourth quarter and full year 2024. Today’s audited accounts include adjustments to EBITDA and net loss compared to the end-January preliminary figures following the sale of the Safe Concordia completed ...

Wall Street has witnessed severe volatility in 2025 after recording an astonishing bull run in the last two years. Year to date, all three major stock indexes — the Dow, the S&P 500 and the Nasdaq Composite — are in negative territory. The small-cap benchmarks — the Russell 2000 and the S&P 600 — are also in the negative zone year to date. Similarly, the mid-cap-specific S&P 400 Index is also in the red. Despite this headwind, a handful of mid-cap stocks are flying high providing more than 25% returns year ...

Reynolds Consumer Products (REYN) came out with quarterly earnings of $0.23 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.23 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post earnings of $0.58 per share when it actually produced earnings of $0.58, delivering no surprise. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Reynolds Consumer Products ...

Group 1 - BioSyent Inc. will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto on May 5 and 6, 2025 [1] - Mr. René Goehrum, President and CEO, will provide an overview of the company's business and corporate activities on May 5 at 11:30am EDT [1] - One-on-one meetings with Mr. Goehrum can be scheduled by registered attendees through the conference portal [2] Group 2 - BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative healthcare products [3] - The company supports healthcare professionals by marketing its products through community, specialty, and international business units [3] - As of the press release date, BioSyent has 11,254,638 common shares outstanding [4]

Core Insights - The report presents the financial statements of WisdomTree Multi Asset Issuer Public Limited Company for the year ended December 31, 2024, indicating the company's performance and financial health [1]. Financial Performance - The financial statements include detailed information on the company's revenue, expenses, and net income for the fiscal year, which are crucial for assessing the company's profitability and operational efficiency [1]. - The report highlights any significant changes in financial metrics compared to previous years, providing insights into growth trends and potential areas of concern [1]. Regulatory Compliance - The document serves as a regulatory filing, ensuring that the company adheres to the necessary financial reporting standards and transparency requirements set by relevant authorities [1]. - It includes disclosures that are essential for investors and stakeholders to understand the company's financial position and compliance status [1].

Core Insights - The Ordinary General Meeting of Amber Grid Shareholders approved the audited consolidated and separate financial statements and the consolidated annual report for the year 2024 [1] - The distribution of profits for AB Amber Grid for 2024 was also approved during the meeting [1] Financial Performance - Revenue for 2024 was EUR 74.6 million, a decrease from EUR 82.2 million in 2023, representing a decline of approximately 9.6% [3] - EBITDA for 2024 was EUR 26.5 million, slightly up from EUR 26.3 million in 2023, indicating a marginal increase of about 0.8% [3] - Net profit for 2024 was EUR 8.3 million, down from EUR 13.0 million in 2023, reflecting a decrease of approximately 36.2% [3]

分组1 - Ionis Pharmaceuticals reported a quarterly loss of $0.75 per share, better than the Zacks Consensus Estimate of a loss of $1.11, and improved from a loss of $0.98 per share a year ago, representing an earnings surprise of 32.43% [1] - The company posted revenues of $132 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 9.86%, and compared to year-ago revenues of $119 million [2] - Ionis Pharmaceuticals has surpassed consensus EPS estimates for four consecutive quarters [2] 分组2 - The stock has underperformed the market, losing about 14.7% since the beginning of the year, while the S&P 500 declined by 5.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.85 on revenues of $146.33 million, and for the current fiscal year, it is -$3.31 on revenues of $637.57 million [7] - The Zacks Industry Rank for Medical - Drugs is in the top 20% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Company Performance - SurModics reported a quarterly loss of $0.13 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.06, and a decline from earnings of $0.07 per share a year ago, resulting in an earnings surprise of -116.67% [1] - The company posted revenues of $28.09 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 8.73%, and down from $31.96 million in the same quarter last year [2] - SurModics has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates two times in the same period [2] Stock Performance - SurModics shares have declined approximately 21.9% since the beginning of the year, compared to a decline of 5.5% for the S&P 500 [3] - The current Zacks Rank for SurModics is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.01 on revenues of $30.47 million, and for the current fiscal year, it is -$0.01 on revenues of $124.01 million [7] - The estimate revisions trend for SurModics is mixed, and changes in earnings expectations may occur following the recent earnings report [6] Industry Context - The Medical - Products industry, to which SurModics belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact SurModics' stock performance [5]